Tag: PD-1 blockade
-
Radiomics Outperforms Clinical Models for NPC Immunotherapy Outcomes
Revolutionizing NPC management with radiomics Nasopharyngeal carcinoma (NPC) remains challenging, with many patients presenting at locally advanced stages. Immunotherapy, including PD-1 blockade, has improved outcomes but durable benefit is limited to a subset. The quest for robust, non-invasive biomarkers to predict response and guide treatment has become urgent. Key multicenter study shows radiomics outperforms clinical…
-
Radiomics Surpasses Clinical Models in NPC Treatment Outcome Prediction
Groundbreaking Insight: Radiomics Elevates NPC Immunotherapy Prediction Nasopharyngeal carcinoma (NPC) remains a highly aggressive cancer, with most patients presenting at locally advanced stages. While immune checkpoint inhibitors, including PD-1 blockade, have reshaped treatment strategies, only a subset of patients derives durable benefit. A multicenter study led by Prof. Shuixing Zhang and Prof. Bin Zhang from…